Loading
A phase 1 trial of LTZ-301 run by LTZ Therapeutics, Inc., now recruiting.
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma is a phase 1 interventional study registered as NCT07121946 by LTZ Therapeutics, Inc., with 42 participants planned, started 2026-01-29. Conditions recorded: Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL) and Marginal Zone Lymphoma (MZL). Interventions recorded: LTZ-301, LTZ-301 and LTZ-301.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares LTZ Therapeutics and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/